Abstract
Adrenocortical carcinoma (ACC) is an aggressive and rare neoplasm that originates in the cortex of the adrenal gland. The disease is associated with heterogeneous but mostly poor outcomes and lacks effective pharmaceutical treatment options. Multi-omics studies have defined the landscape of molecular alterations in ACC. Specific molecular signatures can be detected in body fluids, potentially enabling improved diagnostic applications for patients with adrenal tumours. Importantly, pan-molecular data sets further reveal a spectrum within ACC, with three major subgroups that have different disease outcomes. These new subgroups have value as prognostic biomarkers. Research has revealed that the p53–RB and the WNT–β-catenin pathways are common disease drivers in ACC. However, these pathways remain difficult to target by therapeutic interventions. Instead, a unique characteristic of ACC is steroidogenic differentiation, which has emerged as a potential treatment target, with several agents undergoing preclinical or clinical investigations. Finally, a large proportion of ACC tumours have genetic profiles that are associated with promising therapeutic responsiveness in other cancers. All these opportunities now await translation from the laboratory into the clinical setting, thereby offering a real potential of improved survival outcomes and increased quality of life for patients with this serious condition.
Key points
-
Adrenocortical carcinoma (ACC) is an ultra-rare disease that is associated with poor outcomes; surgery, mitotane-based and platinum-based chemotherapy remain the only effective therapeutic strategies.
-
Ongoing clinical trials include two phase III trials (ADIUVO and ADIUVO-2) as well as multiple phase II studies.
-
Two large consortia have characterized the landscape of molecular alterations in ACC, which included high chromosomal aneuploidy, and the most common driver genes are TP53 and CTNNB1.
-
Three molecular subtypes of ACC have been defined that correlate with prognosis; related surrogate biomarkers that are adopted for clinical use have been described.
-
Up to 50% of metastatic ACCs might harbour genetic aberrations associated with treatment efficacy in other diseases; evaluating a precision oncology approach based on these features will require implementation of new clinical trial designs.
Similar content being viewed by others
References
McAteer, J. P., Huaco, J. A. & Gow, K. W. Predictors of survival in pediatric adrenocortical carcinoma: a Surveillance, Epidemiology, and End Results (SEER) program study. J. Pediatr. Surg. 48, 1025–1031 (2013).
Kerkhofs, T. M. et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur. J. Cancer 49, 2579–2586 (2013).
Cronin, K. A. et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 124, 2785–2800 (2018).
Fassnacht, M. et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115, 243–250 (2009).
Wang, X. et al. Characteristics of The Cancer Genome Atlas cases relative to U.S. general population cancer cases. Br. J. Cancer 119, 885–892 (2018).
Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400–416 (2018).
Lam, A. K. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr. Pathol. 28, 213–227 (2017).
Lloyd, R. V., Osamura, R. Y., Kloppel, G. & Rosai, J. WHO Classification of Tumours of Endocrine Organs 4th edn (IARC, 2017).
Weiss, L. M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 8, 163–169 (1984).
Fassnacht, M. et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 179, G1–G46 (2018). This publication reports the first focused clinical guidelines of ACC.
Berruti, A. et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur. Urol. 65, 832–838 (2014).
Abiven, G. et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J. Clin. Endocrinol. Metab. 91, 2650–2655 (2006).
Weiss, L. M., Medeiros, L. J. & Vickery, A. L. Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13, 202–206 (1989).
Beuschlein, F. et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J. Clin. Endocrinol. Metab. 100, 841–849 (2015). This study establishes the major role of cell proliferation in ACC prognosis.
Morimoto, R. et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr. J. 55, 49–55 (2008).
Libe, R. et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann. Oncol. 26, 2119–2125 (2015).
Fassnacht, M. et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J. Clin. Endocrinol. Metab. 95, 4925–4932 (2010).
Lubitz, J. A., Freeman, L. & Okun, R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223, 1109–1112 (1973).
Fassnacht, M., Libe, R., Kroiss, M. & Allolio, B. Adrenocortical carcinoma: a clinician’s update. Nat. Rev. Endocrinol. 7, 323–335 (2011).
Berruti, A. et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J. Clin. Oncol. 28, e401–e402 (2010).
Terzolo, M. et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 356, 2372–2380 (2007).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00777244 (2019).
Megerle, F. et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 103, 1686–1695 (2018).
Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012). This paper reports the first randomized study in ACC.
Creemers, S. G. et al. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. Endocr. Relat. Cancer 23, R43–R69 (2016).
Le Tourneau, C. et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J. Immunother. Cancer 6, 111 (2018). This paper is the most relevant study on treatment with anti-PD-L1 antibody in ACC.
Henning, J. E. K. et al. Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. J. Clin. Endocrinol. Metab. 102, 4323–4332 (2017).
Fassnacht, M. et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 16, 426–435 (2015). This study is the first randomized placebo controlled study in ACC.
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Zheng, S. et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29, 723–736 (2016). This report presents the largest and most comprehensive molecular analysis of ACC.
Hines, J. M. et al. High-resolution, accurate-mass (HRAM) mass spectrometry urine steroid profiling in the diagnosis of adrenal disorders. Clin. Chem. 63, 1824–1835 (2017).
Taylor, D. R. et al. A 13-steroid serum panel based on LC-MS/MS: use in detection of adrenocortical carcinoma. Clin. Chem. 63, 1836–1846 (2017).
Akerstrom, T., Carling, T., Beuschlein, F. & Hellman, P. Genetics of adrenocortical tumours. J. Intern. Med. 280, 540–550 (2016).
Faillot, S. & Assie, G. Endocrine tumours: the genomics of adrenocortical tumors. Eur. J. Endocrinol. 174, R249–R265 (2016).
Assie, G. et al. Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 46, 607–612 (2014). This paper presents the first pan-molecular characterization of a large number of ACC tumours.
Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304 (2018). This paper reports a pan-cancer analysis of 10,000 cancer cases that puts ACC in perspective.
Crona, J. et al. RNA-sequencing analysis of adrenocortical carcinoma, pheochromocytoma and paraganglioma from a pan-cancer perspective. Cancers 10, 518 (2018).
Else, T. & Rodriguez-Galindo, C. 5th International ACC Symposium: hereditary predisposition to childhood ACC and the associated molecular phenotype: 5th International ACC Symposium Session: not just for kids! Hormones Cancer 7, 36–39 (2016).
Wasserman, J. D. et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children’s oncology group study. J. Clin. Oncol. 33, 602–609 (2015).
Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990).
Huang, K. L. et al. Pathogenic germline variants in 10,389 adult cancers. Cell 173, 355–370 (2018).
Raymond, V. M. et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 98, E119–E125 (2013).
Herrmann, L. J. et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 97, E476–E485 (2012).
Raymond, V. M. et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J. Clin. Oncol. 31, 3012–3018 (2013).
Weksberg, R., Shuman, C. & Beckwith, J. B. Beckwith-Wiedemann syndrome. Eur. J. Hum. Genet. 18, 8–14 (2010).
Skogseid, B. et al. Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 118, 1077–1082 (1995).
Gatta-Cherifi, B. et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d’etude des Tumeurs Endocrines database. Eur. J. Endocrinol. 166, 269–279 (2012).
Naylor, E. W. & Gardner, E. J. Adrenal adenomas in a patient with Gardner’s syndrome. Clin. Genet. 20, 67–73 (1981).
Pilati, C. et al. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. J. Pathol. 242, 10–15 (2017).
Morin, E. et al. Carney complex with adrenal cortical carcinoma. J. Clin. Endocrinol. Metab. 97, E202–E206 (2012).
Sidhu, S. et al. Comparative genomic hybridization analysis of adrenocortical tumors. J. Clin. Endocrinol. Metab. 87, 3467–3474 (2002).
Kjellman, M. et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J. Clin. Endocrinol. Metab. 84, 730–735 (1999).
Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676–689 (2018).
Liu, T. et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr. Relat. Cancer 21, 427–434 (2014).
Juhlin, C. C. et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 100, E493–E502 (2015).
Barthel, F. P. et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat. Genet. 49, 349–357 (2017).
Else, T., Giordano, T. J. & Hammer, G. D. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 93, 1442–1449 (2008).
Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385 (2018).
Knijnenburg, T. A. et al. Genomic and molecular landscape of DNA damage repair deficiency across the Cancer Genome Atlas. Cell Rep. 23, 239–254 (2018).
Robinson, D. R. et al. Integrative clinical genomics of metastatic cancer. Nature 548, 297–303 (2017).
Ross, J. S. et al. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. J. Clin. Pathol. 67, 968–973 (2014).
De Martino, M. C. et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J. Clin. Endocrinol. Metab. 98, 4080–4088 (2013).
Lippert, J. et al. Targeted molecular analysis in adrenocortical carcinomas: a strategy towards improved personalized prognostication. J. Clin. Endocrinol. Metab. 103, 4511–4523 (2018). This paper presents the first comprehensive validation of ENS@T and TCGA studies.
Vatrano, S. et al. Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas. Mod. Pathol. 31, 1257–1269 (2018).
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
Gara, S. K. et al. Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. Nat. Commun. 9, 4172 (2018).
Pinto, E. M. et al. Genomic landscape of paediatric adrenocortical tumours. Nat. Commun. 6, 6302 (2015). This report is the largest and most comprehensive genetic characterization of paediatric ACC tumours.
Giordano, T. J. et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 15, 668–676 (2009).
de Reynies, A. et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27, 1108–1115 (2009).
Lalli, E. Adrenocortical development and cancer: focus on SF-1. J. Mol. Endocrinol. 44, 301–307 (2010).
Barreau, O. et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 98, E174–E184 (2013).
Jouinot, A. et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J. Clin. Endocrinol. Metab. 102, 923–932 (2017).
Mohan, D. R. et al. Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.ccr-18-2693 (2019).
Tissier, F. et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 65, 7622–7627 (2005).
Creemers, S. G. et al. Identification of mutations in cell-free circulating tumor DNA in adrenocortical carcinoma: a case series. J. Clin. Endocrinol. Metab. 102, 3611–3615 (2017).
Garinet, S. et al. Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. Endocr. Relat. Cancer 25, L13–L17 (2018).
Pinzani, P. et al. Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study. J. Clin. Endocrinol. Metab. 98, 3731–3738 (2013).
Patel, D. et al. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. Surgery 154, 1224–1228 (2013).
Chabre, O. et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr. Relat. Cancer 20, 579–594 (2013).
Szabo, D. R. et al. Analysis of circulating microRNAs in adrenocortical tumors. Lab. Invest. 94, 331–339 (2014).
Perge, P. et al. Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors. Endocr 59, 280–287 (2018).
Perge, P. et al. Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors. Sci. Rep. 7, 5474 (2017).
Arlt, W. et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J. Clin. Endocrinol. Metab. 96, 3775–3784 (2011).
Bancos, I. & Arlt, W. Diagnosis of a malignant adrenal mass: the role of urinary steroid metabolite profiling. Curr. Opin. Endocrinol. Diabetes Obes. 24, 200–207 (2017).
Sbiera, S. et al. Assessment of VAV2 expression refines prognostic prediction in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 102, 3491–3498 (2017).
Pinto, E. M. et al. Identification of clinical and biologic correlates associated with outcome in children with adrenocortical tumors without germline TP53 mutations: a St Jude Adrenocortical Tumor Registry and Children’s Oncology Group Study. J. Clin. Oncol. 35, 3956–3963 (2017).
Terzolo, M. et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur. J. Endocrinol. 169, 263–270 (2013).
Hermsen, I. G. et al. Plasma concentrations of o, p’DDD, o, p’DDA, and o, p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J. Clin. Endocrinol. Metab. 96, 1844–1851 (2011).
Sbiera, S. et al. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology 156, 3895–3908 (2015). This paper proposes SOAT1 as the molecular target of mitotane and remains to be validated.
Ronchi, C. L. et al. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr. Relat. Cancer 16, 907–918 (2009).
Malandrino, P. et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr. Relat. Cancer 17, 797–807 (2010).
Laufs, V. et al. ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. Eur. J. Endocrinol. 178, 183–190 (2018).
Roca, E. et al. Topoisomerase 2alpha and thymidylate synthase expression in adrenocortical cancer. Endocr. Relat. Cancer 24, 299–307 (2017).
Ruggiero, C. et al. Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. Sci. Signal. 10, eaal2464 (2017).
Fiorentini, C. et al. Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: a preclinical study. J. Clin. Endocrinol. Metab. 101, 4594–4602 (2016).
Hahner, S. et al. [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 97, 914–922 (2012).
Dominick, M. A. et al. Subacute toxicity of a novel inhibitor of acyl-CoA: cholesterol acyltransferase in beagle dogs. Fundam. Appl. Toxicol. 20, 217–224 (1993).
LaPensee, C. R. et al. ATR-101, a selective and potent inhibitor of acyl-CoA acyltransferase 1, induces apoptosis in H295R adrenocortical cells and in the adrenal cortex of dogs. Endocrinology 157, 1775–1788 (2016).
Langlois, D. K. et al. ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing’s syndrome. BMC Endocr. Disord. 18, 24 (2018). This paper provides proof of concept for ATR-101 as a novel agent for the treatment of endocrine disorders.
Winqvist, O., Karlsson, F. A. & Kampe, O. 21-hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet 339, 1559–1562 (1992).
Tamborero, D. et al. A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin. Cancer Res. 24, 3717–3728 (2018).
Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).
Connell, C. M. et al. Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. Ann. Oncol. 28, 1678–1679 (2017).
Cosentini, D. et al. Immunotherapy failure in adrenocortical cancer: where next? Endocr. Connect. 7, E5–E8 (2018).
Papewalis, C. et al. Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. Clin. Endocrinol. 65, 215–222 (2006).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02465060 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02925234 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03583710 (2019).
Hazim, A. & Prasad, V. A pooled analysis of published, basket trials in cancer medicine. Eur. J. Cancer 101, 244–250 (2018).
Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B. & Fassnacht, M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin. Endocrinol. 75, 585–591 (2011).
Berruti, A. et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, vii131–vii138 (2012).
Fiorentini, C. et al. Palbociclib inhibits proliferation of human adrenocortical tumor cells. Endocrine 59, 213–217 (2018).
Hadjadj, D. et al. A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas. Aging 9, 2695–2716 (2017).
Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. https://doi.org/10.1200/PO.17.00011 (2017).
Flynn, R. L. et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347, 273–277 (2015).
Koschmann, C. et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci. Transl Med. 8, 328ra28 (2016).
Thomas, A. et al. Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J. Clin. Oncol. 36, 1594–1602 (2018).
Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N. Engl. J. Med. 375, 2550–2560 (2016).
Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382–1392 (2012).
Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697–1708 (2015).
Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523–533 (2017).
Hainsworth, J. D. et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J. Clin. Oncol. 36, 536–542 (2018).
Ronchi, C. L. et al. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocr. Relat. Cancer 22, 531–543 (2015).
Simon, D. P., Giordano, T. J. & Hammer, G. D. Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma. Clin. Cancer Res. 18, 2452–2464 (2012).
Tuxen, I. V. et al. Copenhagen Prospective Personalized Oncology (CoPPO) — clinical utility of using molecular profiling to select patients to phase I trials. Clin. Cancer Res. 25, 1239–1247 (2019).
Acknowledgements
J.C. acknowledges the support of Akademiska Sjukhuset, Cancerfonden, Tore Nilsons Stiftelse and Wallenberg Stiftelsen. F.B. acknowledges the support of the Deutsche Forschungsgemeinschaft (DFG) within the CRC/Transregio 205/1 (‘The Adrenal: Central Relay in Health and Disease’).
Reviewer information
Nature Reviews Endocrinology thanks R. Ribeiro and other, anonymous reviewer(s) for their contribution to the peer review of this work.
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding authors
Ethics declarations
Competing interests
J.C. received lecture honoraria from Novartis and honoraria for educational material from NET Connect (funded by Ipsen). F.B. has received funding from HRA Pharma and Ipsen.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
OncoKB Precision Oncology Knowledge Database: http://oncokb.org/
Glossary
- R0 resection
-
Absence of cancer cells at the resection margin by microscopic analysis.
- Neoadjuvant treatment
-
Ancillary therapy administered before main therapy.
- Adjuvant therapy
-
Ancillary therapy administered after main therapy.
- Adrenal adenomas
-
Benign tumour lesions of the adrenal cortex.
Rights and permissions
About this article
Cite this article
Crona, J., Beuschlein, F. Adrenocortical carcinoma — towards genomics guided clinical care. Nat Rev Endocrinol 15, 548–560 (2019). https://doi.org/10.1038/s41574-019-0221-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-019-0221-7
- Springer Nature Limited
This article is cited by
-
Coincidence of primary adrenocortical carcinoma and melanoma: three CASE reports
BMC Endocrine Disorders (2023)
-
DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma
Clinical Epigenetics (2023)
-
Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner
Nature Aging (2023)
-
CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle
Journal of Translational Medicine (2022)
-
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis
Journal of Translational Medicine (2022)